CAI as reported
Caris Life Sciences, Inc. reported $990M of revenue over the trailing twelve months, +85% on the year before. 9 reported series are charted on this page, each one as filed.
$990M
Revenue, trailing twelve months · to Q2 2026 · +85% against the twelve months before
- Net Income
- $105M
Net Income · −138% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $24M
Free Cash Flow · −117% year on year · trailing twelve months to Q2 2026
- Op Margin
- 14%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $990M | +85% | Q2 2026 |
| Net Income | $105M | −138% | Q2 2026 |
| EPS | $1.69 | −111% | Q2 2026 |
| Op Margin | 14% | n/a | Q2 2026 |
| Net Margin | 9.7% | n/a | Q2 2026 |
| ROE | −6.8% | n/a | Q2 2026 |
| ROA | −3.4% | n/a | Q2 2026 |
| ROIC | 7.1% | n/a | Q2 2026 |
| Free Cash Flow | $24M | −117% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Caris Life Sciences, Inc. (CAI) - Revenue & ProfitRevenue & ProfitCaris Life Sciences, Inc. (CAI)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com